S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
New AI Stock Payouts (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.0032
▼
$0.0162
50-Day Range
$0.02
▼
$0.02
52-Week Range
$0.00
▼
$0.50
Volume
31,816 shs
Average Volume
1.54 million shs
Market Capitalization
$1.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

RUBY stock logo

About Rubius Therapeutics (NASDAQ:RUBY) Stock

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

RUBY Price History

RUBY Stock News Headlines

August 2, 2023 | uk.finance.yahoo.com
RUBY - Rubius Therapeutics, Inc.
July 25, 2023 | morningstar.com
North American Morning Briefing: Alphabet, -2-
September 26, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
March 2, 2023 | finance.yahoo.com
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives
February 14, 2023 | marketwatch.com
Thinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?
February 14, 2023 | msn.com
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
January 25, 2023 | yahoo.com
The Wrap: Ruby's moving to Congress Street, launching new French concept
January 12, 2023 | mirror.co.uk
Ruby Wax sparks concern from fans after posting video from hospital bed
September 26, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
January 12, 2023 | dailymail.co.uk
Ruby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting book
November 18, 2022 | finance.yahoo.com
Former Rubius CEO jumps to another Flagship spinout
November 4, 2022 | finance.yahoo.com
Rubius Therapeutics lays off most of its staff, explores sale
November 3, 2022 | finance.yahoo.com
Rubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternatives
November 2, 2022 | seekingalpha.com
Rubius stock falls over 5% after hours on strategic review, more job cuts
November 2, 2022 | finance.yahoo.com
Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
October 28, 2022 | finance.yahoo.com
Rubius Therapeutics, Inc. (RUBY)
October 10, 2022 | reuters.com
Rubius Therapeutics Inc
September 19, 2022 | bizjournals.com
Flagship-backed Vesalius lays off 43%
September 19, 2022 | finance.yahoo.com
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 14, 2022 | bizjournals.com
Rubius Therapeutics lays off 75% of staff, looks to sell Smithfield facility
September 13, 2022 | finance.yahoo.com
Rubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer Assets
September 13, 2022 | finance.yahoo.com
Rubius Therapeutics scraps platform, lays off 160
September 13, 2022 | seekingalpha.com
Rubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforce
September 13, 2022 | nasdaq.com
Rubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick Facts
September 13, 2022 | finance.yahoo.com
Rubius Therapeutics Announces Strategic Update
September 12, 2022 | financialpost.com
Rubius Therapeutics to Provide Strategic Update
September 7, 2022 | msn.com
Peering Into Rubius Therapeutics's Recent Short Interest
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Company Calendar

Last Earnings
11/08/2021
Today
9/25/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
CUSIP
N/A
CIK
1709401
Web
www.rubiustx.com
Phone
(508) 543-1720
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-179,670,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-212.29%
Return on Assets
-86.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.54
Quick Ratio
2.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
0.10

Miscellaneous

Outstanding Shares
90,480,000
Free Float
85,687,000
Market Cap
$1.46 million
Optionable
Not Optionable
Beta
2.34
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Laurence A. Turka M.D. (Age 65)
    Chief Scientific Officer and Head of Research & Translational Medicine
    Comp: $626.55k
  • Mr. Craig R. Jalbert CIRA (Age 61)
    Pres, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director
  • Ms. Marissa Hanify
    Director of Corp. Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RUBY Stock - Frequently Asked Questions

How have RUBY shares performed in 2023?

Rubius Therapeutics' stock was trading at $0.1750 at the beginning of 2023. Since then, RUBY stock has decreased by 90.8% and is now trading at $0.0162.
View the best growth stocks for 2023 here.

When is Rubius Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our RUBY earnings forecast.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) EPS.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $0.02.

How much money does Rubius Therapeutics make?

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $1.46 million. The company earns $-179,670,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (508) 543-1720 or via email at ir@rubiustx.com.

This page (NASDAQ:RUBY) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -